Lior Shaltiel
Algemeen Directeur bij NUREXONE BIOLOGIC INC.
Vermogen: - $ op 30-04-2024
Profiel
Dr. Lior Shaltiel is a Chief Executive Officer & Director at NurExone Biologic Ltd.
and a Chief Executive Officer & Director at NurExone Biologic, Inc. He is on the Board of Directors at NurExone Biologic Ltd.
and NurExone Biologic, Inc.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
NUREXONE BIOLOGIC INC
-.--% | 08-05-2023 | 0 ( -.--% ) | - $ | 30-04-2024 |
Actieve functies van Lior Shaltiel
Bedrijven | Functie | Begin |
---|---|---|
NUREXONE BIOLOGIC INC. | Algemeen Directeur | 01-04-2021 |
NurExone Biologic Ltd.
NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Algemeen Directeur | 01-04-2021 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
NUREXONE BIOLOGIC INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
NurExone Biologic Ltd.
NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Health Technology |